2024-05 – 2023 Annual Report
Serodus ASA - Publishes 2023 Annual Report Download it here
2024-04 – Q1 2024 Reporting
As a consequence of Board decision in December 2023, screening of new patients is stopped. The last patient last visit will be August 2024. Report expected to be finalized in…
2024-01 – Q4 2023 Reporting
After an initial increasing in screening and randomization activities of patients to the SER150 CL-009 study in New Zealand this has slowed down. Recruitment of patients in Australia remains very…
2023-09 – Q2 2023 Reporting
Screening of patients in New Zealand has now improved after visiting the clinical centres involved in SER150 CL-009 study. To facilitate enrolment, the entrance criteria will be revised for the…
2023-06 – Investor Meeting in Copenhagen
Address: Stokholmsgade 412100 Copenhagen E June 21, 2023, at 15:00Please reserve the date
2023-05 – Serodus ASA – Notice of General Meeting 2023
Read more here Norwegian VPS registred shareholders: VPS General Meeting
2023-05 – 2022 Annual Report
Serodus ASA - Publishes 2022 Annual Report Download it here
2023-04 – Q1 2023 Reporting
Serodus has visited all clinical centers in Australia and New Zealand SER150/placebo dosing period has been prolonged from 3 to 6 months. Read more here